IRX Therapeutics
New York, US · Delaware corporation
Founders & leadership
JW
John W. Hadden IIExecutive
JH
Jeffrey HwangExecutive
CP
Curtis P. RobbExecutive
ZR
Zygmund RothExecutive
Board
JD
John D. HalpernBoard director
GP
George P. Denny IIIBoard director
DH
David H. DemingBoard director
FM
Ferid MuradBoard director
JT
John T. SpitznagelBoard director
LM
Lawrence M. WolfBoard director
Reported raises · per SEC filings
Form D private placements$97.3M disclosed across 5 rounds · 2014–2016
▶$33.2MraisedAug 2017 · 98 investors · BiotechnologyRule 506(b)
▶$33.2MraisedAug 2017 · 98 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark W. LeuchtenbergerExecutive Officer, Director
- John D. HalpernDirector
- Ferid MuradDirector
- Lawrence M. WolfDirector
- Edmund TruellDirector
- Charles R. CheringtonDirector
- Zygmund RothExecutive Officer
- David H. DemingDirector
- Monil ShahExecutive Officer
- Curtis P. RobbExecutive Officer
- George P. Denny IIIDirector
- Offering amount
- $33.2M
- Amount sold
- $33.2M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.4MraisedNov 2016 · 4 investors · BiotechnologyRule 506(b)
▶$6.4MraisedNov 2016 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Zygmund RothExecutive Officer
- George P. Denny IIIDirector
- Ferid MuradDirector
- Lawrence M. WolfDirector
- Charles R. CheringtonDirector
- John W. Hadden IIExecutive Officer, Director
- David H. DemingDirector
- John D. HalpernDirector
- Curtis P. RobbExecutive Officer
- Jeffrey HwangExecutive Officer
- Offering amount
- $8M
- Amount sold
- $6.4M
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedMay 2016 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedMay 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Curtis P. RobbExecutive Officer
- Charles R. CheringtonDirector
- Zygmund RothExecutive Officer
- George P. Denny IIIDirector
- John W. Hadden IIExecutive Officer, Director
- David H. DemingDirector
- Lawrence M. WolfDirector
- John D. HalpernDirector
- Jeffrey HwangExecutive Officer
- Ferid MuradDirector
- Offering amount
- $15M
- Amount sold
- $2M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40.6MraisedAug 2015 · 230 investors · BiotechnologyRule 506(b)
▶$40.6MraisedAug 2015 · 230 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John W. Hadden IIExecutive Officer, Director
- John D. HalpernDirector
- Jeffrey HwangExecutive Officer
- Curtis P. RobbExecutive Officer
- David H. DemingDirector
- Zygmund RothExecutive Officer
- George P. Denny IIIDirector
- Ferid MuradDirector
- John T. SpitznagelDirector
- Lawrence M. WolfDirector
- Offering amount
- $40.6M
- Amount sold
- $40.6M
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.1MraisedMar 2014 · 104 investors · BiotechnologyRule 506(b)
▶$15.1MraisedMar 2014 · 104 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ferid MuradDirector
- Lawrence M. WolfDirector
- George P. Denny IIIDirector
- David H. DemingDirector
- Zygmund RothExecutive Officer
- Curtis P. RobbExecutive Officer
- John W. Hadden IIExecutive Officer, Director
- John D. HalpernDirector
- Jeffrey HwangExecutive Officer
- John T. SpitznagelDirector
- Offering amount
- $18M
- Amount sold
- $15.1M
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has IRX Therapeutics raised?
- IRX Therapeutics has disclosed $97.3M raised across 5 rounds.
- Where is IRX Therapeutics headquartered?
- IRX Therapeutics is headquartered in New York, US.